HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of Concern

CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, PARIS – September 23, 2021 – HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and single-cell science, today announced a publication in Science in collaboration with the Coronavirus Immunotherapy Consortium (CoVIC), a global, academic-industry, non-profit research alliance that was established to accelerate discovery, optimization, and delivery of life-saving antibody-based therapeutics against SARS-CoV-2. The publication titled “Defining variant-resistant epitopes targeted SARS-CoV-2 antibodies: A Global Consortium Study” details the analysis of functional groups among an array of SARS-CoV-2 neutralizing antibody candidates that may provide a framework for selecting antibody cocktails to treat and prevent the emergence of resistance variants.

HiFiBiO has identified multiple SARS-CoV-2 neutralizing antibodies with the potential for both therapeutic and prophylactic applications. As part of this project, HiFiBiO submitted 10 distinct mono- or bispecific antibodies to CoVIC for in vitro and in vivo testing, several of which are featured in this publication. One of the company’s top performing candidates was Enuzovimab (HFB30132A), a unique antibody that binds to the majority of the amino acids in the receptor binding domain (RBD) that interact with the human ACE2 receptor. In a recently completed clinical trial in healthy volunteers (NCT04590430), Enuzovimab was well tolerated and non-immunogenic at all doses tested, exhibited extended half-life in the blood, and distributed to the respiratory mucosa. With a half-life longer than most antibodies, Enuzovimab is expected to provide prolonged protection against SARS-CoV-2 infection.

To read the full paper, please visit here.

About Enuzovimab (HFB30132A)

Enuzovimab is an anti-SARS-CoV-2 recombinant antibody engineered with specific sequences identified from the B cells of a COVID-19 convalescent patient. The antibody binds to the viral spike protein with high affinity and has demonstrated potent neutralization of live virus infections in vitro and in vivo. Enuzovimab efficiently neutralizes a panel of SARS-CoV-2 S protein variants including the dominant Alpha and Delta variants.

About HiFiBiO Therapeutics

HiFiBiO Therapeutics is a clinical stage biotech company advancing a robust pipeline targeting both innate and adaptive immunity to treat cancer and autoimmune disease. Our proprietary and versatile DIS® single-cell platform enables the rapid discovery of novel antibody therapeutics with predictive biomarkers through our internal development programs and strategic collaborations. Our passionate team across three continents embraces a fast-paced and engaging work environment to bring transformative medicines to patients. www.hifibio.com.